The Prader-Willi syndrome (PWS) therapeutic sector is witnessing a dramatic transformation as multiple pharmaceutical giants accelerate their development programs targeting this complex genetic disorder. While Soleno’s VYKAT XR maintains its position as a frontrunner, an unprecedented wave of innovative therapeutic candidates is emerging to revolutionize patient care. This therapeutic renaissance represents a watershed moment for… Read.